Blood test for cancer detection company Grail rakes in $390M in latest round

Blood test for cancer detection company Grail rakes in $390M in latest round

Source: 
Endpoints
snippet: 

Just over a week after Third Rock-backed Thrive unveiled ‘real world’ data from a large study evaluating the ability of its blood test to sniff out early signs of cancer in individuals with no history of the disease, rival Grail has raised a gargantuan $390 million in its latest round of financing.